Lectin, Galactoside-Binding, Soluble, 3 Binding Protein (LGALS3BP) Kits ELISA

The galectins are a family of beta-galactoside-binding proteins implicated in modulating cell-cell and cell-matrix interactions. De plus, nous expédions LGALS3BP Anticorps (121) et LGALS3BP Protéines (6) et beaucoup plus de produits pour cette protéine.

list all ELISA KIts Gène GeneID UniProt
LGALS3BP 3959 Q08380
LGALS3BP 245955 O70513
LGALS3BP 19039 Q07797
Comment commander chez anticorps-enligne
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Commandez enligne
  • orders@anticorps-enligne.fr

Top LGALS3BP Kits ELISA sur anticorps-enligne.fr

Showing 4 out of 12 products:

Catalogue No. Reactivité Sensibilité Gamme Images Quantité Livraison Prix Détails
Humain 0.63 ng/mL 1.56 - 100 ng/mL SDS-PAGE of Protein Standard from the Kit  (Highly purified E. coli-expressed recombinant human LGALS3BP). Mouse Capture antibody from the kit in WB with Positive Control: Human HepG2 cell lysate. 96 Tests 12 to 14 Days
Souris 0.069 ng/mL 0.15 ng/mL - 10 ng/mL 96 Tests 13 to 16 Days
Rat 0.2 0.78   96 Tests 15 to 18 Days
Boeuf (Vache)
  96 Tests 15 to 18 Days

LGALS3BP Kits ELISA mieux référencés

  1. Human LGALS3BP Kit ELISA pour Sandwich ELISA - ABIN817381 : Nirala, Gohil: Effect of garlic component s-allyl cysteine sulfoxide on glycated human serum albumin induced activation of endothelial cells: an in vitro study. dans European review for medical and pharmacological sciences 2015 (PubMed)
    Show all 3 Pubmed References

  2. Human LGALS3BP Kit ELISA pour Sandwich ELISA - ABIN6730946 : Ferrín, Ranchal, Llamoza, Rodríguez-Perálvarez, Romero-Ruiz, Aguilar-Melero, López-Cillero, Briceño, Muntané, Montero-Álvarez, De la Mata: Identification of candidate biomarkers for hepatocellular carcinoma in plasma of HCV-infected cirrhotic patients by 2-D DIGE. dans Liver international : official journal of the International Association for the Study of the Liver 2015 (PubMed)

Plus Kits ELISA pour LGALS3BP partenaires d'interaction

Human Lectin, Galactoside-Binding, Soluble, 3 Binding Protein (LGALS3BP) interaction partners

  1. Mac-2 binding protein glycosylation isomer (M2BPGi] might be able to detect liver fibrosis with great sensitivity

  2. Serum M2BPGi level significantly decreases after nucleoside analogue treatment in chronic hepatitis B patients.

  3. Our results showed that serum Gal-3 and Gal-9 should not be considered biomarkers of inflammatory bowel disease. Despite not being a specific marker for Crohn's Disease, serum Gal-3BP might be used as an adjuvant biomarker for disease activity.

  4. M2BPGi is a surrogate marker for assessing hepatic stellate cells (HSC) activation. These findings may reveal the roles of HSCs in extrahepatic fibrotic disease progression. [Review]

  5. M2BPGi is a very useful, easily applicable clinical indicator associated with hepatocellular carcinoma development in chronic hepatitis B patients virologically well controlled with nucleot(s)ide analogues therapy; higher levels of serum M2BPGi at 48 weeks was independent risk factors for hepatocellular carcinoma development.

  6. Mac-2 binding protein glycosylation isomer is a novel liver fibrosis marker

  7. Gal-3BP expression is induced in viral infection and by a multitude of molecules that either mimic or are characteristic for an ongoing inflammation and microbial infection. It belongs to the scavenger receptor cysteine-rich (SRCR) domain-containing protein family, by virtue of its N-terminal SRCR domain. Review.

  8. High serum levels of Mac-2 binding protein glycosylation isomer (M2BPGi) increased hepatocellular carcinoma risk by 4-5 folds. If M2BPGi is below the threshold (0.68 cut-off index), there is > 99% chance that the patient will not develop liver cancer in the subsequent 15 years.

  9. M2BP is highly expressed in advanced carotid artery plaques and significantly correlated with clinical ischemic manifestations.

  10. that Multiple coagulation factor deficiency protein 2 promotes cancer metastasis by regulating lectin mannose binding 1 and level of galactoside-binding soluble 3 binding protein expression levels

  11. In a large cohort of patients with the full spectrum of NAFLD, WFA+ -M2BP levels predicted the presence of advanced disease and correlated strongly with fibrosis stage.

  12. Serum M2BP might contribute to the inflammatory process in systemic lupus erythematosus.

  13. M2BP inhibits both HIV-1 Env processing and virion production.M2BP traps HIV-1 Gag to vimentin filaments to inhibit the transportation of HIV-1 Gag to the plasma membrane.

  14. Results showed that 90K destabilizes E-cadherin and affects cell adhesion and invasion in subconfluent cancer cells via dissociation of the E-cadherin-p120-catenin complex, suggesting that 90K drives less confluent tumor cells into the early steps of cancer metastasis.

  15. Low LGALS3BP expression is associated with HIV infections.

  16. Data suggest that serum levels of RBP4 and LGAL3BP are up-regulated after menopause when complicated by NAFLD (non-alcoholic fatty liver disease); RBP4 and LGAL3BP may serve as biomarkers of NAFLD in postmenopausal women. (RBP4 = retinol binding protein 4; LGAL3BP = galectin-3 binding protein)

  17. Elevated plasma M2BP levels might be predictive of unstable plaque and were associated independently with poor cardiovascular outcomes in patients with acute coronary syndromes.

  18. Serum Mac-2-binding protein expression predicts disease severity in chronic hepatitis C patients.

  19. A higher pre-treatment WFA+-M2BP level was associated with an increased risk of HCC development in patients with undetectable HBV DNA under NA therapy.

  20. the combination of 17-AAG and PI3K/Akt inhibitor would effectively suppress acquired resistance to 17-AAG. In conclusion, targeting of LGALS3BP-mediated-specific survival signaling pathway in resistant cells may provide a novel therapeutic model for the cancer therapy.

Mouse (Murine) Lectin, Galactoside-Binding, Soluble, 3 Binding Protein (LGALS3BP) interaction partners

  1. Using a mouse stasis model of venous thrombosis, we found that gal3bp and gal3 were localized on vein wall, red blood cells, platelets, and microparticles, whereas leukocytes expressed gal3 only.

  2. These findings suggest a novel immunoinhibitory function for LGALS3BP that might be important for immune evasion of tumor cells during cancer progression.

  3. Data give novel evidence that CyCAP regulates the post-translational modification of tissue transglutaminase through its colocalization with calnexin in endoplasmic reticulum.

  4. CyC-AP is an important factor for the regulation of MMP-13 expression

  5. Cyclophilin C-associated protein is expressed in skin and during wound repair. It is regulated by IFNgamma and may function on immune defense in macrophages, lymphocytes, dermal fibroblasts and keratinocytes during wound healing.

  6. CyCAP-deficient mice spontaneously and after challenge with carcinogen develop significantly more colorectal mucosal hyperplasia, an early stage in murine colonic carcinogenesis

Cow (Bovine) Lectin, Galactoside-Binding, Soluble, 3 Binding Protein (LGALS3BP) interaction partners

  1. The relative abundance of PIBF, LGALS1, LGALS3, LGALS3BP, and LGALS9 mRNA would display a differential expression pattern in the endometrium.

LGALS3BP profil antigène

Antigen Summary

The galectins are a family of beta-galactoside-binding proteins implicated in modulating cell-cell and cell-matrix interactions. LGALS3BP has been found elevated in the serum of patients with cancer and in those infected by the human immunodeficiency virus (HIV). It appears to be implicated in immune response associated with natural killer (NK) and lymphokine-activated killer (LAK) cell cytotoxicity. Using fluorescence in situ hybridization the full length 90K cDNA has been localized to chromosome 17q25. The native protein binds specifically to a human macrophage-associated lectin known as Mac-2 and also binds galectin 1.

Gene names and symbols associated with LGALS3BP

  • galectin 3 binding protein (LGALS3BP) anticorps
  • galectin 3 binding protein (Lgals3bp) anticorps
  • lectin, galactoside-binding, soluble, 3 binding protein (Lgals3bp) anticorps
  • calcium activated nucleotidase 1 (CANT1) anticorps
  • lectin, galactoside-binding, soluble, 3 binding protein a (lgals3bpa) anticorps
  • 90K anticorps
  • BTBD17B anticorps
  • CyCAP anticorps
  • lgals3bp anticorps
  • Mac-2 BP anticorps
  • MAC-2-BP anticorps
  • MAC-2BP anticorps
  • MAC2BP anticorps
  • Ppicap anticorps
  • Tango10b anticorps
  • zgc:136780 anticorps

Protein level used designations for LGALS3BP

L3 antigen , MAC2BP , Mac-2-binding protein , basement membrane autoantigen p105 , galectin-3-binding protein , lectin galactoside-binding soluble 3-binding protein , mac-2 BP , serum protein 90K , transport and golgi organization 10 homolog B , tumor-associated antigen 90K , cyCAP , cyp-C-associated protein , mac-2-binding protein , mama , peptidylprolyl isomerase C-associated protein , protein 90K , galectin 3 binding protein , galectin-3-binding protein A , lectin galactoside-binding soluble 3-binding protein A , Lectin galactoside-binding soluble 3-binding protein , Mac-2 BP , Pancreas cancer-associated protein 4 , pancreas cancer-associated protein 4

3959 Homo sapiens
245955 Rattus norvegicus
19039 Mus musculus
531137 Bos taurus
483345 Canis lupus familiaris
100352316 Oryctolagus cuniculus
677742 Danio rerio
101825995 Mesocricetus auratus
Fournisseurs de qualité sélectionnés pour LGALS3BP (LGALS3BP) Kits ELISA
Avez-vous cherché autre chose?